David Hochman Buys 5,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

Posted by Stanley Muller on May 21st, 2026

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report) insider David Hochman acquired 5,000 shares of Orchestra BioMed stock in a transaction on Friday, May 15th. The stock was purchased at an average cost of $3.77 per share, with a total value of $18,850.00. Following the purchase, the insider directly owned 1,059,029 shares of the company’s stock, valued at approximately $3,992,539.33. This trade represents a 0.47% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Orchestra BioMed Trading Down 0.5%

Shares of Orchestra BioMed stock opened at $3.98 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03. Orchestra BioMed Holdings, Inc. has a 52 week low of $2.20 and a 52 week high of $5.42. The stock has a 50 day moving average price of $4.26 and a two-hundred day moving average price of $4.27. The stock has a market capitalization of $238.33 million, a PE ratio of -4.10 and a beta of 0.52.

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.92 million. As a group, equities analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on OBIO shares. B. Riley Financial dropped their target price on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Weiss Ratings lowered Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Wall Street Zen lowered Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Orchestra BioMed in a report on Thursday, May 14th. Finally, Chardan Capital restated a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, March 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Orchestra BioMed has a consensus rating of “Moderate Buy” and an average price target of $13.60.

Read Our Latest Stock Analysis on Orchestra BioMed

Institutional Trading of Orchestra BioMed

A number of hedge funds have recently bought and sold shares of the business. Knott David M Jr lifted its holdings in Orchestra BioMed by 1.5% during the first quarter. Knott David M Jr now owns 253,651 shares of the company’s stock worth $1,078,000 after acquiring an additional 3,651 shares during the period. Citadel Advisors LLC lifted its holdings in Orchestra BioMed by 9.2% during the third quarter. Citadel Advisors LLC now owns 54,002 shares of the company’s stock worth $134,000 after acquiring an additional 4,561 shares during the period. Bank of America Corp DE lifted its holdings in Orchestra BioMed by 35.7% during the second quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock worth $58,000 after acquiring an additional 5,678 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Orchestra BioMed during the fourth quarter worth $38,000. Finally, Virtu Financial LLC bought a new stake in Orchestra BioMed during the fourth quarter worth $57,000. 53.20% of the stock is currently owned by institutional investors.

Key Stories Impacting Orchestra BioMed

Here are the key news stories impacting Orchestra BioMed this week:

Positive Sentiment: Multiple insiders bought shares, including Director Eric Fain’s purchase of 20,000 shares and additional buying by insider David Hochman and Director Jason Aryeh. Insider accumulation is often viewed as a signal that management believes the stock is undervalued. SEC filing for Eric Fain purchase
Positive Sentiment: HC Wainwright reiterated a Buy rating on OBIO and maintained a $10 price target while slightly lifting some earnings estimates, reinforcing Wall Street’s view that the stock has meaningful upside from current levels. Benzinga report
Positive Sentiment: Orchestra BioMed said management will participate in the Jefferies Global Healthcare Conference, which could increase visibility with investors and potential strategic partners. Conference announcement
Neutral Sentiment: B. Riley Financial lowered its price target to $10 from $12 but kept a Buy rating, so the message was mixed rather than outright negative. Benzinga report

Orchestra BioMed Company Profile

(Get Free Report)

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.